Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
Melina Rodriguez, Founder of Health Evidence Digest, Senior Medical Editor at Precision AQ, shared a post on LinkedIn:
“Imaavy (Nipocalimab) Receives FDA Approval as the First-Ever Treatment Proven Safe and Effective Specifically for Warm Autoimmune Hemolytic Anemia, Ending Decades of Off-Label Management With Non-Specific Immunosuppression.
On August 24, 2026, the FDA approved Imaavy (nipocalimab-aahu, Johnson and Johnson) as the first-ever treatment proven safe and effective for warm autoimmune hemolytic anemia.
Phase 2/3 ENERGY showed approximately 3x more patients achieved durable hemoglobin response versus placebo; mean hemoglobin improvement began at week 1.
Here is how FcRn blockade selectively reduces pathogenic IgG without broad immunosuppression and what the complete trial data shows….”
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community
-
Aug 29, 2026, 15:49Ujjawal Agarwal: Alkem’s Fight Against Anemia in Rural Bihar
-
Aug 29, 2026, 15:44Christopher Cannon: Anticoagulation Shows Benefits Even in Low Risk Atrial Fibrillation Patients